OGA and type 2 diabetes mellitus: Nunoi et al. reported that both urinary N-acetyl-beta-d-glucosaminidase (NAG) and β2-microglobulin were decreased after the initiation of tofogliflozin, with significant negative correlations seen between changes in these markers and their corresponding baseline values in patients with type 2 diabetes and macroalbuminuria based on an integrated analysis of four phases 2 and 3 studies [34].